InpatientView, individual code level report

A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability

Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.

Employers Health’s Alexis Sova says employers excluding GLP-1s now lean on weight management programs and direct-to-employer deals, not a hard cutoff.

Approximately two-thirds of Employers Health clients now exclude GLP-1s for obesity, up from a roughly even split at launch as cost drives coverage decisions.

Chad Hatfield, Pharm.D., MHA, BCPS, of UC Davis Health, discusses the system's pharmacy shared service center, embedded pharmacists and 340B rebate readiness.

Blood tests reveal early, widespread inflammation in hidradenitis suppurativa, linking biomarkers to disease severity, quality of life, smoking, and potential cardiovascular risk.

UCLA research suggests that GLP-1 therapies may protect bone health in Type 2 diabetes patients.

A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.